azathioprine has been researched along with Rheumatism in 62 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To discuss the relationship between the genotype of thiopurine methyltransferase (TPMT) and azathioprine tolerance in the patients with rheumatic diseases." | 7.74 | [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases]. ( Huang, M; Li, H; Liang, LQ; Wang, YX; Yang, XY; Zhan, ZP, 2007) |
| "We report 14 cases of secondary myelodysplastic syndromes (sMDS) following treatment with azathioprine for non-malignant disorders." | 7.73 | Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. ( Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Richter, J, 2005) |
| " Methotrexate, azathioprine, mycophenolate mofetil, cyclosporin cyclophosphamide, chlorambucil, and other related drugs have potential benefits in the treatment of severe and/or recalcitrant rheumatic skin diseases." | 4.81 | Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders. ( Callen, JP, 2001) |
| "Azathioprine is a useful immunosuppressive agent in Beçhet's disease." | 3.77 | Immunosuppressive drug therapy for rheumatic disease. ( Bayliss, GE; McCune, WJ, 1991) |
| "To discuss the relationship between the genotype of thiopurine methyltransferase (TPMT) and azathioprine tolerance in the patients with rheumatic diseases." | 3.74 | [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases]. ( Huang, M; Li, H; Liang, LQ; Wang, YX; Yang, XY; Zhan, ZP, 2007) |
| "We report 14 cases of secondary myelodysplastic syndromes (sMDS) following treatment with azathioprine for non-malignant disorders." | 3.73 | Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. ( Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Richter, J, 2005) |
| "We describe a 67-year-old white man with Wegener's granulomatosis who was treated with cyclophosphamide, then with azathioprine, and who subsequently developed cytomegalovirus retinitis." | 3.67 | Cytomegalovirus retinitis in rheumatic disease: a case report. ( Finan, MJ; Pressly, T; Roberts, R; Winkler, A, 1987) |
| " During treatment with the basic drugs: gold, D-penicillamine and chloroquine, pregnancy should be avoided." | 3.65 | [Problems of rheumatic therapy in pregnancy (author's transl)]. ( Bischof, P, 1976) |
| " In IBD, conventional weight-based dosing with thiopurines leads to an inadequate response in many patients." | 2.50 | The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. ( Friedman, AB; Gibson, PR; Sparrow, MP, 2014) |
| " TB risk was higher when anti-TNF agents were combined with methotrexate or azathioprine as compared with either controls (24/4241 versus 0/4673; OR 54; 95% CI 5." | 2.50 | Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. ( Armuzzi, A; Bruzzese, V; Diamanti, AP; Gatta, L; Hassan, C; Laganà, B; Lorenzetti, R; Migliore, A; Ridola, L; Zullo, A, 2014) |
| "Azathioprine is a valuable alternative to slow-acting antirheumatic drugs in older patients with rheumatoid arthritis." | 2.38 | Azathioprine, cyclophosphamide and chlorambucil. ( Bacon, PA; Luqmani, RA; Palmer, RG, 1990) |
| "Infection and disease exacerbation are the leading reasons for ICU admission in systemic rheumatic diseases." | 1.72 | Determination of the main causes, outcome, and prognostic factors of patients with rheumatologic diseases admitted to the medical intensive care unit in Southern Iran. ( Arjmand, M; Fallahi, MJ; Shahriarirad, R; Shenavandeh, S, 2022) |
| "As sarcoidosis is a mimicking disease, a good differential diagnosis should be made to avoid misdiagnosis and in order not to be late in diagnosis and treatment." | 1.72 | Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience. ( Duruöz, MT; Esen, İ; Gezer, HH; Karabulut, Y; Öz, N, 2022) |
| "Short episodes of corticosteroids seem to be safe in HBV carriers, even in the presence of DMARDs, but lamivudine prophylaxis should be considered for patients exposed to biologicals or cyclophosphamide." | 1.43 | Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study. ( Balbir-Gurman, A; Braun, M; Braun-Moscovici, Y; Markovits, D; Nahir, MA; Saadi, T, 2016) |
| "Azathioprine (AZA) is a commonly used drug for the management of various rheumatologic disorders." | 1.36 | Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline. ( Gow, PJ; Jabin, D; Kumar, S, 2010) |
| " Polymerase chain reaction (PCR) tests provide a sensitive, specific means of prospectively identifying these patients before AZA therapy and minimizing toxicity through dosage reduction." | 1.31 | Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. ( Anis, AH; Esdaile, JM; Marra, CA, 2002) |
| "In addition to any increased risk of malignancy that may be conferred by individual rheumatic diseases, there is a further risk of specific types of malignancy that is related to the duration of exposure to immunosuppressive drugs." | 1.30 | Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. ( Asten, P; Barrett, J; Symmons, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (33.87) | 18.7374 |
| 1990's | 12 (19.35) | 18.2507 |
| 2000's | 15 (24.19) | 29.6817 |
| 2010's | 10 (16.13) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Arjmand, M | 1 |
| Shahriarirad, R | 1 |
| Shenavandeh, S | 1 |
| Fallahi, MJ | 1 |
| Karabulut, Y | 1 |
| Öz, N | 1 |
| Gezer, HH | 1 |
| Esen, İ | 1 |
| Duruöz, MT | 1 |
| Yang, J | 1 |
| Wang, P | 1 |
| Qin, Z | 1 |
| Jia, M | 1 |
| Zhang, C | 1 |
| Tian, X | 1 |
| Zheng, Y | 1 |
| Zhang, A | 1 |
| Zhang, X | 1 |
| Liu, S | 1 |
| Broen, JCA | 1 |
| van Laar, JM | 1 |
| Su, SS | 1 |
| Lin, YF | 1 |
| Zhou, H | 1 |
| Polk, BI | 1 |
| Becker, ML | 2 |
| Xuan, D | 1 |
| Yu, Y | 1 |
| Shao, L | 1 |
| Wang, J | 1 |
| Zhang, W | 1 |
| Zou, H | 1 |
| Friedman, AB | 1 |
| Sparrow, MP | 1 |
| Gibson, PR | 1 |
| Lorenzetti, R | 1 |
| Zullo, A | 1 |
| Ridola, L | 1 |
| Diamanti, AP | 1 |
| Laganà, B | 1 |
| Gatta, L | 1 |
| Migliore, A | 1 |
| Armuzzi, A | 1 |
| Hassan, C | 1 |
| Bruzzese, V | 1 |
| Braun-Moscovici, Y | 1 |
| Braun, M | 1 |
| Saadi, T | 1 |
| Markovits, D | 1 |
| Nahir, MA | 1 |
| Balbir-Gurman, A | 1 |
| Mimori, T | 1 |
| Jabin, D | 1 |
| Kumar, S | 1 |
| Gow, PJ | 1 |
| Matsumoto, I | 1 |
| Miller, AV | 1 |
| Ranatunga, SK | 1 |
| Siva, C | 1 |
| Yokoyama, WM | 1 |
| McLeod, HL | 3 |
| Seidman, EG | 1 |
| Furst, DE | 1 |
| Marra, CA | 1 |
| Esdaile, JM | 1 |
| Anis, AH | 1 |
| Mayer, DF | 1 |
| Kushwaha, SS | 1 |
| Mitnick, H | 1 |
| Jacobowitz, G | 1 |
| Krinsky, G | 1 |
| Eberle, M | 1 |
| Rosenzweig, B | 1 |
| Willis, D | 1 |
| Rockman, C | 1 |
| Riles, T | 1 |
| Knipp, S | 1 |
| Hildebrandt, B | 1 |
| Richter, J | 1 |
| Haas, R | 1 |
| Germing, U | 1 |
| Gattermann, N | 1 |
| Zhan, ZP | 2 |
| Yang, XY | 2 |
| Liang, LQ | 2 |
| Wang, YX | 2 |
| Huang, M | 2 |
| Lian, F | 1 |
| Payne, K | 1 |
| Newman, W | 1 |
| Fargher, E | 1 |
| Tricker, K | 1 |
| Bruce, IN | 1 |
| Ollier, WE | 1 |
| Glück, T | 1 |
| Müller-Ladner, U | 1 |
| Li, H | 1 |
| Vroom, F | 1 |
| van Roon, EN | 1 |
| van den Berg, PB | 1 |
| Brouwers, JR | 1 |
| de Jong-van den Berg, LT | 1 |
| Turner, RA | 1 |
| Johnson, JA | 1 |
| Semble, EL | 1 |
| Jones, SM | 1 |
| Calin, A | 1 |
| Solinger, AM | 1 |
| Hess, EV | 1 |
| Bermas, BL | 1 |
| Hill, JA | 1 |
| Ramsey-Goldman, R | 1 |
| Schilling, E | 1 |
| McCune, J | 1 |
| Singer, NG | 1 |
| Black, AJ | 1 |
| Capell, HA | 1 |
| Powrie, RH | 1 |
| Matowe, LK | 1 |
| Pritchard, SC | 1 |
| Collie-Duguid, ES | 1 |
| Reid, DM | 1 |
| Asten, P | 1 |
| Barrett, J | 1 |
| Symmons, D | 1 |
| Ishioka, S | 1 |
| Hiyama, K | 1 |
| Sato, H | 1 |
| Yamanishi, Y | 1 |
| Kumagai, K | 1 |
| Maeda, H | 1 |
| Yamakido, M | 1 |
| Ichikawa, Y | 1 |
| Pickenpack, A | 1 |
| Straub, RH | 1 |
| Distler, O | 1 |
| Hammond, A | 1 |
| Oellerich, M | 1 |
| Schölmerich, J | 1 |
| Lang, B | 1 |
| Schütz, E | 1 |
| Balakrishnan, C | 1 |
| Mangat, G | 1 |
| Kalke, S | 1 |
| Desai, D | 1 |
| Joshi, A | 1 |
| Deshpande, RB | 1 |
| Joshi, VR | 1 |
| Callen, JP | 1 |
| Pirofsky, B | 1 |
| Bardana, EJ | 1 |
| Faust-Tinnefeldt, G | 1 |
| Brinkrolf, H | 1 |
| Mathies, H | 1 |
| Evens, RP | 1 |
| Bischof, P | 1 |
| James, DG | 1 |
| Friedmann, AI | 1 |
| Graham, E | 1 |
| McCune, WJ | 2 |
| Friedman, AW | 1 |
| Bayliss, GE | 1 |
| Luqmani, RA | 1 |
| Palmer, RG | 1 |
| Bacon, PA | 1 |
| Clements, PJ | 1 |
| Davis, J | 1 |
| O'Callaghan, JW | 1 |
| Brooks, PM | 1 |
| Winkler, A | 1 |
| Finan, MJ | 1 |
| Pressly, T | 1 |
| Roberts, R | 1 |
| Dugowson, CE | 1 |
| Gilliland, BC | 1 |
| Ostensen, M | 1 |
| Husby, G | 1 |
| Tsokos, GC | 1 |
| Balow, JE | 1 |
| Huskisson, EC | 1 |
| Meadow, SR | 1 |
| Glasgow, EF | 1 |
| White, RH | 1 |
| Moncrieff, MW | 1 |
| Cameron, JS | 1 |
| Ogg, CS | 1 |
| Klein, G | 1 |
| Fellner, S | 1 |
| Fellner, R | 1 |
| Rothermich, NO | 1 |
| Mayr, E | 1 |
| Kahn, MF | 1 |
| Krampac, I | 1 |
| Pavkovceková, O | 1 |
| Démant, F | 1 |
| Tischler, V | 1 |
| Mydlík, M | 1 |
| Jurkovic, I | 1 |
| Prekop, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| he Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease (3M-RGD Trial): an Open-label, Randomized Trial[NCT06068179] | Phase 2/Phase 3 | 205 participants (Anticipated) | Interventional | 2023-10-08 | Not yet recruiting | ||
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for azathioprine and Rheumatism
| Article | Year |
|---|---|
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.
Topics: Antirheumatic Agents; Azathioprine; Biological Products; Biomarkers; Child; Genome, Human; Genotype; | 2013 |
Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Cohort Studies; Derm | 2014 |
The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.
Topics: Animals; Anti-Inflammatory Agents; Azathioprine; Drug Interactions; Gastrointestinal Agents; Humans; | 2014 |
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Certolizumab Pe | 2014 |
[Immunosuppressants].
Topics: Azathioprine; Calcineurin Inhibitors; Collagen Diseases; Cyclophosphamide; Cyclosporine; Humans; Imm | 2009 |
[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 4. Azathioprine].
Topics: Azathioprine; Collagen Diseases; Humans; Immunosuppressive Agents; Rheumatic Diseases | 2011 |
Immunotherapies in rheumatologic disorders.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl | 2012 |
Pharmacogenomics in pediatric rheumatology.
Topics: Antimetabolites; Antirheumatic Agents; Azathioprine; Biological Products; Child; Humans; Methotrexat | 2012 |
Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field.
Topics: Analgesics, Opioid; Antirheumatic Agents; Azathioprine; Drug Design; Drug Interactions; Drug-Related | 2002 |
Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine.
Topics: Antirheumatic Agents; Azathioprine; Drug Monitoring; Genotype; Humans; Methyltransferases; Pharmacog | 2002 |
Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases.
Topics: Autoimmune Diseases; Azathioprine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2003 |
[Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Azathioprine; Biological Pro | 2007 |
Effects of immunosuppressive drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Animals; Azathioprine; Chlorambucil; Cyclophos | 1995 |
Immunosuppressive drug use during pregnancy.
Topics: Adrenal Cortex Hormones; Animals; Azathioprine; Chlorambucil; Cyclophosphamide; Cyclosporine; Female | 1997 |
Immunosuppressive drug treatment.
Topics: Azathioprine; Cyclophosphamide; Humans; Immunization; Immunocompromised Host; Immunosuppressive Agen | 1997 |
Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders.
Topics: Adult; Alkylating Agents; Antimetabolites; Azathioprine; Child; Chlorambucil; Cladribine; Cyclophosp | 2001 |
Immunosuppressive therapy in rheumatic disease.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr | 1977 |
Immunosuppressive drug therapy for rheumatic disease.
Topics: Azathioprine; Chlorambucil; Cyclosporine; Humans; Immunosuppressive Agents; Rheumatic Diseases | 1992 |
Immunosuppressive drug therapy for rheumatic disease.
Topics: Azathioprine; Cyclophosphamide; Cyclosporins; Humans; Immunosuppressive Agents; Mechlorethamine; Rhe | 1991 |
Azathioprine, cyclophosphamide and chlorambucil.
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Connective Tissue Diseases; Cyclophosphamide; Hum | 1990 |
Cytotoxic drugs: their clinical application to the rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Cell Division; Chemica | 1986 |
Disease-modifying agents and immunosuppressive drugs in the elderly.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Antimalarials; Azathioprine; Cyclophosphami | 1986 |
Management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyc | 1986 |
Antirheumatic drug treatment during pregnancy and lactation.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Chloroquine; Cyc | 1985 |
Immunosuppressive agents and plasmapheresis in immunological disorders.
Topics: Animals; Antigen-Antibody Complex; Autoantibodies; Azathioprine; Cyclophosphamide; Glucocorticoids; | 1985 |
An updated look at antirheumatic drugs.
Topics: Allopurinol; Anti-Inflammatory Agents; Arthritis; Azathioprine; Chloroquine; Cyclophosphamide; Gluco | 1967 |
[Antirheumatics. 40].
Topics: Anti-Inflammatory Agents; Antilymphocyte Serum; Azathioprine; Chlorambucil; Female; Humans; Immunosu | 1969 |
[The immunodepressive agents. II. Immunodepressive agents in rheumatic diseases].
Topics: Azathioprine; Chlorambucil; Humans; Immunosuppressive Agents; Rheumatic Diseases; Thiotepa | 1967 |
5 trials available for azathioprine and Rheumatism
| Article | Year |
|---|---|
Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases.
Topics: Antirheumatic Agents; Azathioprine; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2000 |
Immunosuppressive therapy in rheumatic disease.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr | 1977 |
[Azathioprine in long-term therapy of inflammatory rheumatic diseases. Variability of laboratory chemical parameters].
Topics: Alkaline Phosphatase; Azathioprine; Blood Cell Count; Blood Sedimentation; gamma-Glutamyltransferase | 1978 |
Immunosuppressive drug therapy for rheumatic disease.
Topics: Azathioprine; Cyclophosphamide; Cyclosporins; Humans; Immunosuppressive Agents; Mechlorethamine; Rhe | 1991 |
[Indomethacin in rheumatic diseases with special reference to ophthalmologic studies].
Topics: Allopurinol; Arthritis, Rheumatoid; Azathioprine; Blood Cells; Capsules; Clinical Trials as Topic; E | 1972 |
30 other studies available for azathioprine and Rheumatism
| Article | Year |
|---|---|
Determination of the main causes, outcome, and prognostic factors of patients with rheumatologic diseases admitted to the medical intensive care unit in Southern Iran.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Dyspnea; Female; Hospital Mortality; Human | 2022 |
Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience.
Topics: Adrenal Cortex Hormones; Ambulatory Care Facilities; Anti-Inflammatory Agents, Non-Steroidal; Arthri | 2022 |
Topics: Adolescent; Adult; Aged; Alleles; Asian People; Azathioprine; Biomarkers; Child; Female; Genetic Pre | 2019 |
Association of thiopurine S-methyltransferase and NUDT15 polymorphisms with azathioprine-induced myelotoxicity in Chinese patients with rheumatological disease.
Topics: Adolescent; Adult; Asian People; Azathioprine; Humans; Immunosuppressive Agents; Methyltransferases; | 2020 |
Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Azathioprine; Cycl | 2016 |
Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline.
Topics: Antirheumatic Agents; Azathioprine; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follo | 2010 |
Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cost-Benefit Analysis; Decision Support T | 2002 |
Periaortitis: gadolinium-enhanced magnetic resonance imaging and response to therapy in four patients.
Topics: Aged; Anti-Inflammatory Agents; Arteriosclerosis; Azathioprine; Contrast Media; Female; Gadolinium D | 2004 |
Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Cell Transformation, Neoplastic; | 2005 |
[The profile and clinical significance of azathioprine metabolic enzymes activity in rheumatological patients].
Topics: Adolescent; Adult; Azathioprine; Bone Marrow; Drug Tolerance; Erythrocytes; Female; Follow-Up Studie | 2006 |
TPMT testing in rheumatology: any better than routine monitoring?
Topics: Antirheumatic Agents; Azathioprine; Drug Administration Schedule; Drug Monitoring; Humans; Immunosup | 2007 |
[Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases].
Topics: Adolescent; Adult; Analysis of Variance; Azathioprine; Drug Resistance; Female; Gene Frequency; Geno | 2007 |
Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy--a descriptive study.
Topics: Antirheumatic Agents; Azathioprine; Databases, Factual; Drug Prescriptions; Drug Therapy, Combinatio | 2008 |
Antirheumatic drug effects on neutrophil response to chemotactic factors: a comparison of analytical techniques.
Topics: Aspirin; Azathioprine; Chemotactic Factors; Chemotaxis, Leukocyte; Dose-Response Relationship, Drug; | 1983 |
The monitoring of patients on disease-modifying antirheumatoid drugs.
Topics: Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Humans; Methotrexate; Rheumatic Diseases | 1993 |
Rheumatic diseases and AIDS--is the association real?
Topics: Acquired Immunodeficiency Syndrome; Adult; Azathioprine; Female; Humans; Male; Muscular Diseases; Pa | 1993 |
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Hematologic Diseases; Heterozygote; Humans; Male; | 1998 |
Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.
Topics: Aged; Aged, 80 and over; Azathioprine; Europe; Female; Follow-Up Studies; Humans; Immunosuppressive | 1999 |
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese.
Topics: Azathioprine; Genotype; Humans; Immunosuppressive Agents; Japan; Methyltransferases; Mutation; Rheum | 1999 |
Single nucleotide polymorphism to disclose severe side-effects or proper dosage for each patient.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Methyltransferases; Mutation; Polymorphism, Single N | 2000 |
The spectrum of chronic autoimmune hepatitis.
Topics: Adolescent; Adult; Autoantibodies; Azathioprine; Biopsy, Needle; Chronic Disease; Female; Hepatitis | 1998 |
[Azathioprine in rheumatology].
Topics: Arthritis, Rheumatoid; Azathioprine; Chromosome Aberrations; Humans; Immunosuppression Therapy; Lupu | 1979 |
Antirheumatic agents.
Topics: Adrenal Cortex Hormones; Antimalarials; Aspirin; Azathioprine; Chloroquine; Cyclophosphamide; Gold; | 1979 |
[Problems of rheumatic therapy in pregnancy (author's transl)].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Azathioprine; Chloroquine; Female; Fetal Diseases | 1976 |
Uveitis. A series of 368 patients.
Topics: Adolescent; Adult; Aged; Antigen-Antibody Complex; Autoantibodies; Azathioprine; Child; Child, Presc | 1976 |
Cytomegalovirus retinitis in rheumatic disease: a case report.
Topics: Adult; Azathioprine; Cyclophosphamide; Cytomegalovirus Infections; Granulomatosis with Polyangiitis; | 1987 |
Recent drugs and the rheumatic diseases.
Topics: Acetaminophen; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 1974 |
Schönlein-Henoch nephritis.
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Biopsy; Child; Child, Preschool; Cyclophosphamide | 1972 |
[Positive and negative effects of cytostatic therapy in rheumatic patients].
Topics: Antineoplastic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Humans; Mercaptopurine; Methotr | 1970 |
[Immunosuppressive therapy of kidney lesio in Schönlein-Henoch purpura].
Topics: Azathioprine; Child; Female; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Purpura; Rheum | 1970 |